NightHawk Biosciences Announces Completion Of Demonstration Run For A Top-Tier NIH And DTRA Funded Research University

Next phase of multi-million-dollar project to include scaling up cGMP manufacturing for phase 1 trial targeting infectious disease

 

CDMO services attracting considerable interest as state-of-the-art San Antonio facility helps address industry-wide scarcity for large molecule manufacturing

DURHAM, N.C., Dec. 21, 2023 (GLOBE NEWSWIRE) -- NightHawk Biosciences (NYSE:NHWK) ("NightHawk" or the "Company"), an integrated contract development and manufacturing organization (CDMO), today announced its Scorpius BioManufacturing subsidiary ("Scorpius") completed a demonstration run in the Company's process development lab for a microbial vaccine program developed by a top-tier research university that is NIH and DTRA (Defense Threat Reduction Agency) funded.

Jeff Wolf, CEO of NightHawk, commented, "This first phase of a multi-million-dollar project was particularly noteworthy, as we achieved a successful demonstration run following a prior failed attempt by a competitor CDMO. The complexity of the project led this top-tier university to choose Scorpius, drawn by our more engaged management approach and accelerated development timeline. The successful completion of this demonstration run showcases our team's dedication and expertise, and represents an important step in advancing our relationship with this nationally renowned university. The next phase of this project will include scaling up to cGMP manufacturing to support a phase 1 infectious disease trial. Our CDMO services continue to attract considerable interest, thanks to our extraordinary team, state-of-the-art facilities, and the industry-wide scarcity of capacity for large molecule manufacturing."